Parainfluenza virus infections in patients with hematological malignancies or stem cell transplantation: Analysis of clinical characteristics, nosocomial transmission and viral shedding.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
20
09
2021
accepted:
06
07
2022
entrez:
29
7
2022
pubmed:
30
7
2022
medline:
3
8
2022
Statut:
epublish
Résumé
To assess morbidity and mortality of parainfluenza virus (PIV) infections in immunocompromised patients, we analysed PIV infections in a hematology and stem cell transplantation (SCT) unit over the course of three years. Isolated PIV strains were characterized by sequence analysis and nosocomial transmission was assessed including phylogenetic analysis of viral strains. 109 cases of PIV infection were identified, 75 in the setting of SCT. PIV type 3 (n = 68) was the most frequent subtype. PIV lower respiratory tract infection (LRTI) was observed in 47 patients (43%) with a mortality of 19%. Severe leukopenia, prior steroid therapy and presence of co-infections were significant risk factors for development of PIV-LRTI in multivariate analysis. Prolonged viral shedding was frequently observed with a median duration of 14 days and up to 79 days, especially in patients after allogeneic SCT and with LRTI. Nosocomial transmission occurred in 47 patients. Phylogenetic analysis of isolated PIV strains and combination with clinical data enabled the identification of seven separate clusters of nosocomial transmission. In conclusion, we observed significant morbidity and mortality of PIV infection in hematology and transplant patients. The clinical impact of co-infections, the possibility of long-term viral shedding and frequent nosocomial transmission should be taken into account when designing infection control strategies.
Identifiants
pubmed: 35905071
doi: 10.1371/journal.pone.0271756
pii: PONE-D-21-30394
pmc: PMC9337657
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0271756Déclaration de conflit d'intérêts
NG: honoraria from MSD and Roche, advisory board from Pfizer, and travel grants from BMS and Karyopharm; DT – honoraria and travel grants from Gilead, IQone, MSD, and Pfizer, and travel grants from Abbvie, Astellas, Celgene, Jazz; CMT – grants and/or provision of investigational medicinal product from Pfizer, Daiichi Sankyo, and BiolineRx, research support by Deutsche Forschungsgemeinschaft DFG, Deutsche Krebshilfe, BMBF, Wilhelm Sander Stiftung, José Carreras Stiftung, and Bayer AG, and advisory boards from Pfizer, and Janssen-Cilag GmbH. This does not alter our adherence to PLOS ONE policies on sharing data and materials
Références
N Engl J Med. 2020 Dec 24;383(26):2586-2588
pubmed: 33259154
J Clin Virol. 2017 Jul;92:53-55
pubmed: 28531552
Clin Microbiol Rev. 2003 Apr;16(2):242-64
pubmed: 12692097
PLoS One. 2016 Feb 11;11(2):e0148258
pubmed: 26866481
Biol Blood Marrow Transplant. 2019 Jan;25(1):163-171
pubmed: 30149147
Eur J Cancer. 2016 Nov;67:200-212
pubmed: 27681877
Jpn J Infect Dis. 2013;66(1):76-8
pubmed: 23429092
Clin Infect Dis. 2016 Oct 15;63(8):999-1006
pubmed: 27481873
Lancet Respir Med. 2018 Oct;6(10):782-792
pubmed: 30076119
Arch Virol. 2010 Dec;155(12):2083-103
pubmed: 21046175
Medicine (Baltimore). 2006 Sep;85(5):278-287
pubmed: 16974212
J Clin Microbiol. 2007 Jun;45(6):1690-6
pubmed: 17392447
Biol Blood Marrow Transplant. 2016 May;22(5):965-70
pubmed: 26904972
J Infect Dis. 1992 Nov;166(5):995-1005
pubmed: 1328413
J Med Microbiol. 2017 Apr;66(4):502-510
pubmed: 28463659
Blood. 2012 Mar 22;119(12):2738-45; quiz 2969
pubmed: 22246027
J Infect. 2012 Sep;65(3):246-54
pubmed: 22546619
Transpl Infect Dis. 2011 Aug;13(4):433-7
pubmed: 21466639
Clin Infect Dis. 2014 May;58(10):1357-68
pubmed: 24599766
Clin Infect Dis. 2019 Jan 7;68(2):298-305
pubmed: 29961826
Clin Microbiol Rev. 1994 Apr;7(2):265-75
pubmed: 8055470
J Clin Microbiol. 1998 May;36(5):1388-91
pubmed: 9574711
J Med Virol. 2021 Nov;93(11):6371-6376
pubmed: 34324206
Clin Infect Dis. 2013 Jan;56(2):258-66
pubmed: 23024295
Transpl Infect Dis. 2017 Aug;19(4):
pubmed: 28544152
PLoS One. 2020 Mar 10;15(3):e0229355
pubmed: 32155160
Eur J Clin Microbiol Infect Dis. 2003 Feb;22(2):79-84
pubmed: 12627280
Influenza Other Respir Viruses. 2014 Mar;8(2):217-27
pubmed: 24286248
Front Microbiol. 2018 Mar 13;9:391
pubmed: 29593671
Intervirology. 2015;58(1):35-40
pubmed: 25592955
Blood. 2001 Aug 1;98(3):573-8
pubmed: 11468152
Virology. 1990 Jan;174(1):308-13
pubmed: 2152995
Haematologica. 2009 Jun;94(6):833-9
pubmed: 19377073
Mol Biol Evol. 2016 Jul;33(7):1870-4
pubmed: 27004904
Infection. 2013 Dec;41(6):1171-5
pubmed: 23821486
Leukemia. 2020 Jun;34(6):1637-1645
pubmed: 32332856
Biol Blood Marrow Transplant. 2010 Feb;16(2):192-8
pubmed: 19781656
Infect Drug Resist. 2012;5:121-7
pubmed: 22893749
PLoS One. 2012;7(8):e43893
pubmed: 22937119
Cancer Lett. 2016 Jan 28;370(2):358-64
pubmed: 26582658